Reinforcing targeted therapeutics with phenotypic stability factors
1a Life Sciences Division ; Lawrence Berkeley National Laboratory ; Berkeley , CA USA.
Cell Cycle (Georgetown, Tex.)
|December 9, 2014
Summary
Cancer cells adapt to targeted therapies due to genetic variability. Phenotypic stability factors, which limit epithelial-mesenchymal transitions (EMT), may improve targeted cancer therapy success by preventing adaptive resistance.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Deregulated cell cycle progression is a hallmark of cancer, often due to defects in regulatory proteins.
- Targeted therapies exploit these defects but face challenges from tumor heterogeneity and acquired resistance.
- Cancer cell adaptability to therapeutic inhibition is a critical factor in treatment outcomes.
Purpose of the Study:
- To investigate the role of phenotypic stability factors in cancer cell adaptability and therapeutic resistance.
- To explore how phenotypic stability influences compensatory mechanisms, such as cyclin-dependent kinase 2 (CDK2) deregulation.
- To identify strategies for enhancing targeted therapy efficacy against aggressive tumors.
Main Methods:
- Analysis of genetic and epigenetic variability in cancer cells.
- Assessment of phenotypic heterogeneity and its impact on treatment response.
- Investigation of epithelial-mesenchymal transitions (EMT) and their regulation by phenotypic stability factors.
- Evaluation of potential therapeutic agents that modulate phenotypic stability.
Main Results:
- Tumor cells exhibit significant variability in their ability to adapt to targeted therapies.
- Phenotypic stability factors restrict epithelial-mesenchymal transitions (EMT), influencing cellular adaptability.
- Interference with phenotypic stability can prevent compensatory changes, like CDK2 deregulation, which contribute to resistance.
- The adaptability of cells to therapeutic agents varies markedly, highlighting a novel aspect of cancer biology.
Conclusions:
- Phenotypic stability factors are critical determinants of targeted therapy success by limiting adaptive resistance mechanisms.
- Targeting agents that induce or maintain phenotypic stability could overcome therapeutic resistance in aggressive cancers.
- Understanding and manipulating phenotypic stability offers a promising avenue for developing synergistic cancer eradication strategies.
Keywords:
CDK, cyclin-dependent kinaseCSC, cancer stem cellEMT, epithelial-mesenchymal transitionER, estrogen receptorGSI, γ-secretase inhibitorHER2, Human Epidermal Growth Factor Receptor 2NF-κBNICD, Notch intracellular domainNotchOvolTGFβcancer therapycyclin-dependent kinase (CDK)drug resistanceepithelial-mesenchymal transition (EMT)inflammationMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K
01:29Pharmacogenomics: Identification of New Drug Targets
104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K